                         SEQUENCE LISTING

<110>  Dana-Farber Cancer Institute, Inc.
 
<120>  REAGENTS AND METHODS FOR ANALYSIS OF PROTEINS AND METABOLITES 
       TARGETED BY COVALENT PROBES

<130>  00530-0331WO1

<140>  PCT/US2017/063443
<141>  2017-11-28

<150>  US62/427042
<151>  2016-11-28

<160>  11    

<170>  PatentIn version 3.5

<210>  1
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  JNK1-derived peptide

<400>  1

Leu Met Asp Ala Asn Leu Cys Gln Val Ile Gln Met Glu 
1               5                   10              


<210>  2
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  JAK3-derived peptide

<400>  2

Leu Val Met Glu Tyr Leu Pro Ser Gly Cys Leu Arg 
1               5                   10          


<210>  3
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDK12 derived peptide

<400>  3

Met Ala Pro Pro Asp Leu Pro His Trp Gln Asp Cys His Glu Leu Trp 
1               5                   10                  15      


Ser Lys 
        


<210>  4
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ITK derived peptide

<400>  4

His Gly Cys Leu Ser Asp Tyr Leu Arg Ser Gln Arg Gly Leu Phe Ala 
1               5                   10                  15      


Ala Glu 
        


<210>  5
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDK7 derived peptide

<400>  5

Tyr Phe Ser Asn Arg Pro Gly Pro Thr Pro Gly Cys Gln Leu Pro Arg 
1               5                   10                  15      


Pro Asn Cys Pro Val Glu Thr Leu Lys 
            20                  25  


<210>  6
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  EGFR derived peptide

<400>  6

Gly Cys Leu Leu Asp Tyr Val Arg 
1               5               


<210>  7
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic cysteine-containing peptide

<400>  7

Phe Gly Leu Cys Ser Gly Pro Ala Asp Thr Gly Arg 
1               5                   10          


<210>  8
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptides


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X=15N-1, 13C-6 leucine

<400>  8

Tyr Met Ala Asn Gly Cys Leu Xaa Asn Tyr Leu Arg 
1               5                   10          


<210>  9
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TAK1 derived peptide

<400>  9

Ile Cys Asp Phe Gly Thr Ala Cys Asp Ile Gln Thr His Met Thr Asn 
1               5                   10                  15      


Asn Lys 
        


<210>  10
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDK7 derived peptide


<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  X=13C6 -15N4

<400>  10

Tyr Phe Ser Asn Arg Pro Gly Pro Thr Pro Gly Cys Gln Leu Pro Xaa 
1               5                   10                  15      


Arg Pro Asn Cys Pro Val Glu Thr Leu Lys 
            20                  25      


<210>  11
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  X=cysteine residue labeled with DMPIA

<400>  11

Tyr Phe Ser Asn Arg Pro Gly Pro Thr Pro Gly Xaa Gln Leu Pro Arg 
1               5                   10                  15      


Pro Asn Cys Pro Val Glu Thr Leu Lys 
            20                  25  


